logo-loader

Amryt Pharma's Lojuxta approved for funding as NHS treatment

Published: 11:07 10 Jul 2018 BST

David Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT) tells Proactive Investors their Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

1 hour, 26 minutes ago